Company intelligence / Profile preview
Ymmunobio
Basel, Switzerlandymmunobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
YB-200 has received orphan drug status by the US FDA for the treatment of liver cancer in February 2023. The company has demonstrated anti-tumor activity of its lead asset YB-200 in validated models showing correlation with changes in the immune compartment of the tumor microenvironment[5][6].
- Therapeutic areas
- Oncology
- Modalities
- AntibodiesADCs (Antibody-Drug Conjugates)RadiopharmaceuticalsBiTEs (Bispecific T-cell Engagers)Diagnostics
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
EVIIVE (for Liquid Biopsy development)[2]
Beyond the preview
Go deeper on Ymmunobio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ymmunobio.